Introducing KNECT: Upgrade Your KOL ID & Mapping Game with V2V’s Enhanced KOL ID Management Portal

KOL Profile

Filtering a spreadsheet to pinpoint the right expert can often feel like finding a needle in a haystack. You asked for a better solution. We listened. V2V is proud to announce our latest software application for visualizing data of Key Opinion Leader (KOL)/Key External Expert (KEE) Identification and Mapping projects.  

What is KNECT?

KNECT is our upgraded portal-based KOL ID & Mapping platform. This easy-to-navigate interface provides medical affairs, commercial, and clinical teams with unparalleled visibility into KOL/KEE’s influence patterns, all pulled from worldwide expert databases.

Social influence, clinical trials, publications, guideline influence, and more are available at your fingertips. KNECT eliminates the guesswork by providing comprehensive, validated intelligence on each expert. You’ll have confidence knowing that every data point has been verified and curated to ensure you’re connecting with truly credible thought leaders within your therapeutic area along with who they are connected to.

Customization and Scalability

We are fans of innovation. V2V’s in-house development team can also customize and scale the application to fit your business needs and rules, not the other way around.

KOL Profile

Key Features – Simple. Easy to Use. Customizable.

  • Detailed analysis and rankings for expert discovery within any therapeutic area
  • Rich datasets on KOLs (publications, trials, conferences, social media, associations) and more
  • Intuitive search and real-time visual mapping
  • Activity management and engagement tracking
  • Group management and collaboration
  • Social network analysis and influence mapping
  • Cloud-based, secure platform

Work smarter. Work faster. Work with KNECT.

Recent Posts

Man in suit holding back dominos

Will Your Launch Strategy Succeed or Fail?

The Challenge: A Faster, More Complex Launch Environment In today’s pharmaceutical market, strong science is the foundation, but it doesn’t always guarantee a successful launch....

Read More
Story 2

Industry Insights – June 2026

From evolving China deal dynamics and prolonged job searches to the growing push for AI-driven drug repurposing, explore how shifts in BioPharma are redefining innovation,...

Read More
FDA Commissioner Marty Makary, M.D.

Industry Insights – May 2026

Biosimilars are gaining U.S. momentum even as patent thickets keep triggering legal fights, small biotechs are feeling the pressure of the FDA’s faster-moving approval environment,...

Read More